Cenzestotug

申泽苏塔单抗

Report date: 2026/03/31 20:00:21

Base Information

Drug NameCenzestotug
Drug Alias NameRecombinant human anti-OX40 monoclonal antibody (Eucure Biopharma)重组抗OX40人源化单克隆抗体注射液（祐和）YH-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 4 agonists
TargetsTumor necrosis factor receptor superfamily member 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEucure Pharmaceutical Technology (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSyncromune IncEucure Pharmaceutical Technology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A